Revance Therapeutics, Inc.
NASDAQ: RVNC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark J. Foley
- Employees
- 597
- Headquarters
- Nashville, United States
- IPO year
- 2014
- Market cap
- $381.0M
- Website
- https://www.revance.com
Loading RVNC…
Loading profile data…Frequently asked questions about RVNC
What does Revance Therapeutics, Inc. (RVNC) do?
Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for...
Where does RVNC trade?
Revance Therapeutics, Inc. (RVNC) trades on the NASDAQ Global Market.
What sector is RVNC in?
Revance Therapeutics, Inc. (RVNC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Revance Therapeutics, Inc.?
Mark J. Foley is the chief executive officer of Revance Therapeutics, Inc. (RVNC).
Where is Revance Therapeutics, Inc. headquartered?
Revance Therapeutics, Inc. is headquartered in United States.
Does RVNC pay a dividend?
Revance Therapeutics, Inc. (RVNC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RVNC go public?
Revance Therapeutics, Inc. (RVNC) completed its initial public offering in 2014.